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Abstract
Significant left main coronary artery disease is defined as a greater than 50% angio-
graphic narrowing of the vessel. In general, there are three options for the treatment of 
LMCA disease which include optimal medical therapy, percutaneous revascularization, 
or surgical revascularization, either off-pump or on-pump. It is the highest-risk lesion 
subset of ischemic heart disease and until recent years, coronary artery bypass grafting 
was the major choice of treatment. Although there is a marked increase in use of percu-
taneous coronary intervention in left main disease, there are still some questions about 
its efficacy when compared with surgery. Although bypass surgery is the gold standard, 
current treatment guideline recommendations canalized the treatment of this potentially 
lethal disease into percutaneous interventions in selected patients who had low to inter-
mediate anatomic complexity. Left main disease with low SYNTAX scores (≤22) can be 
treated either by bypass surgery or percutaneously, whereas SYNTAX score > 32 is an 
indication for only coronary artery bypass surgery. The heart team should always be in 
collaboration, give therapeutic options to patients and decide the best treatment strategy 
for the welfare of the patient.
Keywords: coronary artery disease, left main coronary artery disease, coronary artery 
bypass surgery, percutaneous intervention, PCI, CABG, SYNTAX score
1. Introduction
Despite its short length, the left main coronary artery (LMCA) is still one of the most chal-
lenging areas of disease for both cardiovascular surgeons and interventional cardiologists 
today. Significant LMCA disease is defined as a greater than 50% angiographic narrowing of 
the vessel. LMCA disease is the highest-risk lesion subset of ischemic heart disease and until 
recent years, coronary artery bypass grafting (CABG) was the major choice of treatment. 
© 2017 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
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Although there is a marked increase in use of percutaneous coronary intervention (PCI) 
in LMCA disease, there are still some questions about its efficacy when compared with 
CABG operations. Starting from the traditional treatment options in LMCA disease, current 
treatment guideline recommendations canalized the treatment of this potentially lethal dis-
ease into PCI in selected patients who had low to intermediate anatomic complexity based 
on some scoring systems. Patient selection for both techniques is important and directly 
affects the clinical outcome. In this chapter, basic characteristics of the LMCA will be dis-
cussed with recommendations of treatment options under the highlights of recent studies 
and guidelines.
2. Importance of LMCA
The LMCA emerges from the aorta within the sinus of Valsalva through the ostia of the left 
aortic cusp. It passes between the pulmonary trunk and the left atrial appendage and just 
under the appendage; the artery divides into the left anterior descending (LAD) and the left 
circumflex coronary arteries (LCx). In one third of the patients, LMCA bifurcates into LAD, 
LCx and ramus intermedius branches [1]. The LMCA is responsible for supplying about 75% 
of the left ventricular (LV) cardiac mass in patients with right dominant type and 100% in 
the case of left dominant type, and as a result, severe LMCA disease will significantly reduce 
blood flow to a large portion of the myocardium and place the patient at high risk for life-
threatening events, such as LV dysfunction and arrhythmias [2].
Significant LMCA disease is defined as greater than 50% angiographic narrowing of the artery 
and was shown to be present in about 4–6% of all patients who underwent coronary angiogra-
phy [3]. Besides, patients with unprotected LMCA (ULMCA) disease treated medically have a 
3-year mortality rate of about 50% [4].
The LMCA is anatomically divided into three portions: origin of LMCA from the aorta 
(ostium), mid portion and the distal portion. The LMCA is different from the other coronary 
arteries because it has relatively greater elastic tissue content; this feature explains the elastic 
recoil and its high restenosis rate, following balloon angioplasty procedures [5]. Since one-
third of patients have trifurcated LMCA, this anatomical feature is important because in distal 
LMCA stenosis, PCI is much more difficult in trifurcated lesions than the bifurcated ones [6]. 
In 1% of the population, the LMCA is absent, and the LAD and LCx arteries originate directly 
from the aorta via separate ostia.
As with other coronary artery disease, the most common cause of LMCA disease is athero-
sclerosis. Non-atherosclerotic causes of LMCA lesions are rare. Other reasons may be either 
obstructive or nonobstructive. Since it is originated directly from the aorta, any disease affect-
ing the ascending aorta can also cause LMCA obstruction such as aortic dissection, external 
compression resulting from aortic aneurysm or tumor, iatrogenic injury resulting from coro-
nary interventions or vasospasm, irradiation, syphilitic aortitis, Takayasu’s arteritis, rheuma-
toid arthritis, aortic valve disease including malposition of prosthesis, aneurismal dilatations 
such as Kawasaki disease and atherosclerotic aneurysms.
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There is a relationship between the length of LMCA and the LMCA segment that is diseased. 
In short LMCAs (<10 mm), the stenosis are more frequently localized at the ostium and then 
at the distal bifurcation (55 vs. 38%), in contrast to long LMCA that develops stenosis more 
frequently near the distal bifurcation compared to near the ostium (77 vs. 18%). The mid seg-
ment of LMS is rarely affected (5–7% of patients). Ostial LMCA stenoses are more common in 
women (44 vs. 20%) [7].
3. Diagnosis of LMCA disease
Most patients with LMCA disease are symptomatic. Since occlusion of this vessel compro-
mises about 75% of blood flow to the LV, patients are at high risk of major cardiovascular 
events unless protected by a collateral flow. The diagnosis of LMCA disease is usually made 
by coronary angiography. The use of noninvasive imaging studies does not specifically distin-
guish LMCA from other types of coronary artery disease. Certain findings on exercise testing 
or, in patients with acute coronary syndromes on the electrocardiogram (ECG), are suggestive 
of LMCA disease. These include diffuse and severe ST-segment deviation or significant ven-
tricular arrhythmias on ECG monitoring or hypotension during exercise [8].
Coronary angiography remains the gold standard diagnostic technique for the diagnosis 
of clinically important LMCA disease, although small but significant number of false-
positive and false-negative results is present with inter-observer variabilities. In order to 
avoid precipitating myocardial ischaemia in patients with severe LMCA disease, opera-
tors try to limit the number of angiographic shots, as well as keep dye injections to a 
minimum: this may have an impact on diagnostic accuracy of less experienced operators. 
Ostial LMCA stenosis is not well shown angiographically; the diagnosis relies on detec-
tion of pressure damping on engagement of the ostia with the catheter tip and the absence 
of reflux of dye into the coronary sinus on injection. Detecting and quantifying stenosis 
of the LMCA and bifurcation rely on a normal segment for comparison: the severity of 
concentric stenoses of the entire LMCA may therefore be underestimated. Angiography 
is also poor at assessing lesion calcification. This is important firstly because where visual 
assessment is inaccurate, it is often because of the presence of calcification, and secondly 
because the presence of calcification is an important risk factor for dissection following 
PCI [9]. Coronary angiographic views of some patients with diagnosis of LMCA disease 
is shown in Figure 1.
In some cases, additional studies including intravascular ultrasound imaging (IVUS), frac-
tional flow reserve (FFR) and coronary vasodilatory reserve (CVR) may be helpful for increas-
ing diagnostic accuracy and decision-making.
IVUS is an intracoronary imaging modality that facilitates the anatomic visualization of the 
vessel lumen and characterizes plaques. It provides a 360° sagittal scan of the vessel from 
the lumen through the media to the vessel wall. It provides additional information such as 
minimal and maximal diameters, cross-sectional area and plaque area compared with coro-
nary angiography alone [9]. IVUS detects calcification twice as often as angiography and is 
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more sensitive at detecting significant LMCA stenosis than angiography alone. IVUS may 
have a role in the assessment of high-risk patients and in deciding whether patients with 
angiographically indeterminate LMCA lesions should undergo PCI or surgery [10]. Since 
IVUS is an effective method to examine the coronary architecture and extent of atheroscle-
rotic plaque with changes in vessel dimensions, it should be considered in angiographically 
borderline lesions as a complimentary method.
FFR is the ratio of distal coronary pressure to aortic pressure measured during maximal 
hyperemia which represents fraction of normal blood flow through a stenotic artery. The 
normal FFR for all vessels under all hemodynamic conditions, regardless of the status of the 
microcirculation, is 1.0. FFR values <0.75 are associated with abnormal stress tests [10]. FFR 
may have a role in deciding whether patients with angiographically mild or moderate LMCA 
disease should undergo revascularization: 56% of patients with FFR <0.75 in one study had 
significant LMCA stenoses [11].
CVR is the ratio of hyperemic to basal flow and reflects flow resistance through the epicardial 
artery and the corresponding myocardial bed. Unlike FFR, the value is affected by the coro-
nary microcirculation and hemodynamic conditions. Although of use in the further assess-
ment of angiographically indeterminate lesions, no studies have specifically addressed the 
use of this diagnostic adjunct in assessment of LMCA disease [10].
A LM pattern on exercise nuclear testing is characterized by perfusion defects in the LAD and 
LCx territories (i.e., reduced nuclear tracer uptake in the septal, anterior and lateral walls). It 
Figure 1. (a–b) Proximal LMCA stenosis at the level of aorto-ostial junction (in circles). (c–d) Acute MI patient with 
distal LMCA stenosis at the level of bifurcation and proximal part of LAD (in circle) and thrombosis of the RCA (arrow). 
(e) After thrombolytic infusion and balloon angioplasty flow in RCA is restored, patient is operated in elective conditions 
for left main disease.
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may also be associated with a picture of “balanced” ischemia where there is uniform diminu-
tion of tracer uptake with stress, often indicative of LM with three-vessel disease. This may 
be accompanied by transient ischemic dilation (TID), which is considered present when the 
image of the left ventricular cavity appears to be significantly greater after stress as compared 
with that at rest [12].
More recently cardiac CT and MRI have been shown to have a high correlation with angiogra-
phy for the diagnosis of LM disease. This may be particularly useful in surveillance imaging 
after revascularization of the LM often performed after stenting [12]. Multislice computed 
tomography (MSCT), also called multidetector coronary angiography, has rapidly gained 
in popularity and applicability. MSCT has a good diagnostic accuracy for detecting more 
than 50% luminal stenosis with a sensitivity of 97% (CI: 94–98%) and specificity of 86% (CI: 
78–90%) compared with quantitative conventional coronary angiography [13, 14].
Cardiovascular magnetic resonance imaging (CMRI) has some advantages and limitations 
compared with cardiac CT imaging. Advantages of CMRI include the absence of ionizing 
radiation and contrast media, as well as no requirement for heart rate control with b-blockers 
[12]. Detection of coronary lesions in heavily calcified coronary segments by CMRI can be 
more reliable than by cardiac CT [15].
There is a strong association between LMCA disease and carotid artery stenosis. Carotid 
artery disease is present in almost 40% of patients undergoing angiography for evaluation of 
angina, with significant left main stem disease, compared with just 5% with single-vessel dis-
ease [16]. The AHA guidelines recommend screening all patients undergoing bypass surgery 
for left main stem disease to identify carotid artery disease [17].
4. Preventive and medical therapies
There are three options for treating LMCA disease: optimal medical therapy, PCI, or surgical 
revascularization (CABG). All patients with LMCA disease should receive preventive thera-
pies to decrease the risk of subsequent cardiovascular events. Preventive therapies include 
smoking cessation, exercise, lipid lowering therapy with stains, management of diabetes 
mellitus with proper oral antidiabetics or insulin and achievement of target blood pressure 
goals with suitable antihypertensive medications. In the 1970s and 1980s, three randomized 
controlled trials (the Veterans Affairs Cooperative Study [18], European Coronary Surgery 
Study [19], and CASS (Coronary Artery Surgery Study) [20]) established the survival ben-
efit of CABG compared with contemporaneous medical therapy without revascularization 
in certain subjects with stable angina. They reported a survival rate of 80–88% for CABG 
and 63–68% for medical treatment only. Subsequently, a 1994 meta-analysis of 7 studies that 
randomized a total of 2649 patients to medical therapy for CABG showed that CABG offered 
a survival advantage over medical therapy for patients with LMCA disease or three-vessel 
coronary artery disease (CAD) [21]. The studies also established that CABG is more effective 
than medical therapy at relieving anginal symptoms.
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5. Treatment of significant LMCA disease
In general, there are three options for the treatment of LMCA disease, which include optimal 
medical therapy, percutaneous revascularization, or surgical revascularization, either off-
pump or on-pump. Hybrid procedures may also be applied according to patient’s clinical 
status or clinician’s choice for different scenarios.
As stated above, CABG offers a survival advantage over medical therapy for significant 
LMCA disease since medical therapy alone has been associated with poor outcomes. CABG 
surgery has been accepted as the standard revascularization method for LMCA disease for 
several decades. In the last decade, several randomized controlled trials have shown favor-
able results for PCI with drug-eluting stents (DES) compared with CABG. In this title of the 
chapter, scoring systems for decision making and treatment strategies for LMCA disease will 
be discussed, mainly focusing on the surgical treatment of LMCA disease.
Compared with the early days, contemporary bypass surgery has been greatly refined. Cardio-
preservation techniques have improved and nearly all patients with LMCA disease receive an 
internal mammary artery (IMA) graft. In addition, patients undergoing surgery are more aggres-
sively treated medically. The outcomes are excellent. When comparing the results of CABG with 
PCI, the coronary stents must perform at least as well as surgery in terms of outcomes [22].
A percutaneous approach for revascularization in LMCA disease has both attractive and 
undesirable features. Surgery needs a long recovery period with significant potential mor-
bidities including postsurgical atrial fibrillation, pleural effusions, infections, delayed wound 
healing, anemia and depression which have negative effects on patient’s quality of life. A 
percutaneous approach is clearly more palatable to patients than surgery. For the physician, 
LM stem is large and easily accessible for PCI techniques. However, especially for the patients 
with absent collateral vasculature, balloon inflation may lead to cardiovascular collapse with 
ischemia. Abrupt vessel closure or subsequent stent thrombosis involving the LM stem may 
be a fatal event. All of these factors must be taken into account and their effect clearly under-
stood when comparing the two revascularization methods [22].
6. Scoring systems for decision-making in LMCA disease
The assessment of patients with LMCA disease both as a candidate for surgery or PCI is often 
a complex procedure and best achieved by the “Heart Team” approach. When one method of 
revascularization is preferred over the other for improved survival, this consideration takes 
precedence over improved symptoms. ACCF/AHA guideline suggests that a Heart Team 
approach to revascularization is recommended in patients with unprotected LM or complex 
CAD (Class I recommendation, Level of evidence; C) [17].
Several risk stratification scores, based on either angiographic or clinical parameters, have 
been developed to evaluate outcomes in patients with LMCA disease who undergo bypass 
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surgery. Despite the use of various objective scoring systems derived from hundreds of thou-
sands of patients, an experienced surgeon who spends time evaluating the coronary angio-
gram, taking a detailed history and examining the patient may provide the most accurate 
assessment of operative risk [22].
The Synergy between PCI with TAXUS and Cardiac Surgery (SYNTAX) score includes factors 
of coronary angiographic complexity rather than clinical factors. Although the limitations of 
using the SYNTAX score for certain revascularization recommendations are recognized, the 
SYNTAX score is a reasonable surrogate for the extent of CAD and its complexity and serves 
as important information that should be considered when making revascularization deci-
sions. Recommendations that refer to SYNTAX scores use them as surrogates for the extent 
and complexity of CAD [17].
ACCF/AHA guideline suggests that calculation of the SYNTAX and STS (The Society of 
Thoracic Surgeons) scores is reasonable in patients with unprotected LM and complex CAD 
(Class IIa recommendation, level of evidence; B). Variables which contribute to the determi-
nation of the score include dominance of the coronary artery system, number of lesions, seg-
ment involved per lesions and presence of chronic total occlusions, trifurcation, bifurcation, 
aorto-ostial lesions, tortuosity, calcification, thrombi, long lesions and/or diffuse disease. By 
the highlights of these variables, a separate number is calculated for each lesion. Then, these 
values are summed up to generate the total SYNTAX score. An online tool for easy calculation 
of the score may be found online at http://www.syntaxscore.com. Some of the steps illustrat-
ing the scoring are shown in Figure 2.
SYNTAX trial is the largest, single published study to date, comparing the outcome of PCI 
vs. CABG in patients with 3-vessel coronary disease and LMCA disease [23]. The higher the 
score, the greater is the extent and the complexity of the disease. The SYNTAX trial strati-
fied the entire randomized population (i.e., both patients with 3-vessel and patients with left 
main coronary artery disease) by tercile of SYNTAX score and found that the patients in the 
lowest tercile (score:0–22) fared just as well with PCI as surgery, whereas those in the high-
est tercile (score ≥ 33) clearly did better with surgery [22, 23]. Capodanno et al. applied the 
SYNTAX score to a registry of 819 patients undergoing LM PCI or surgery and found that the 
outcomes of patients with SYNTAX score ≥ 34 was better with surgery as compared with PCI 
but patients with SYNTAX score < 34 had similar outcomes with surgery or PCI in terms of 
2-year mortality rates [24]. They concluded that a SYNTAX score threshold of 34 may usefully 
identify a cohort of patients with LMCA disease who benefit most from surgical revascular-
ization in terms of mortality.
The SYNTAX study included a subset of 705 patients with LM stem disease and their 5-year 
outcomes have been published [25, 26]. For the overall group with LMCA disease, there 
was no significant difference in the rate of major adverse cardiac and cardiovascular events 
(MACCE), MI, or death at 5 years in patients treated with PCI compared with those treated 
with surgery [26]. The rate of stroke was lower in patients treated with PCI, and the rate of 
repeat revascularization was lower in patients treated with surgery. When the LM cohort 
was divided into two groups based on the SYNTAX score, striking differences between the 
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treatment strategies became apparent. For the high SYNTAX score group (≥33), the rate of 
MACCE was significantly greater in the PCI group compared with surgery. Although not sta-
tistically powered for mortality, the rate of death trended alarmingly higher in the PCI group. 
By contrast, for patients with scores <33, there was no difference in MACCE. Interestingly, 
in this group with low or intermediate scores, there was actually a lower mortality rate with 
PCI [22, 25, 26].
By-time, not only the anatomical assessment, but also the clinical status of the patients was 
added for better evaluation of the risk stratification, mainly on the SYNTAX score. The clinical 
SYNTAX score is a combination of age, creatinine and ejection fraction (ACEF) model and 
SYNTAX scores, and subsequent development of a logistic model has provided better risk 
assessment [27]. The SYNTAX II score is a combination of anatomical and clinical factors (age, 
creatinine clearance, LV function, gender, chronic obstructive pulmonary disease, and periph-
eral vascular disease) and predicts long-term mortality in patients with complex three-vessel 
Figure 2. Some of the steps illustrating the SYNTAX scoring system; available online at: http://www.syntaxscore.com.
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or LMCA disease [28]. It was found to be superior to the conventional SYNTAX score in guid-
ing decision-making between CABG and PCI in the SYNTAX trial and subsequently validated 
in the drug-eluting stent for LMCA disease DELTA registry.
The STS score is a risk-prediction model, validated in patients undergoing cardiac surgery, 
with a specific model for CABG and combined CABG and valve surgery. It can be used to 
predict in-hospital or 30-day mortality and in-hospital morbidity [29]. ESC/EACTS guidelines 
on myocardial revascularization suggest STS score for CABG to assess short-term outcomes 
for CABG (Class IB recommendation) and SYNTAX score for both CABG and PCI to assess 
medium- to long-term (≥1 year) outcomes (Class IB recommendation) [30]. LMCA disease 
with low SYNTAX scores (≤22) should be treated either by CABG or PCI, whereas SYNTAX 
score > 32 is a contraindication for PCI. Recommendations of the ESC/EACTS guidelines for 
LMCA disease are summarized in Table 1.
7. Treatment of LMCA disease with PCI
Although surgery was and still is the main treatment option for unprotected LMCA disease, 
the emerging practice in PCI techniques and new materials has led to almost routine thera-
peutic option for a subset group of patients with LMCA disease. PCI for treatment of unpro-
tected LMCA disease has passed through several phases. The early published experiences of 
balloon angioplasty for LMCA disease were associated with a high procedural mortality and 
poor long-term survival. In the 1980s, O’Keefe et al. reported 9.1% procedural mortality and 
36% 3-year survival rate for 127 acute and elective cases with LMCA disease for coronary 
angioplasty [31]. In the following years, coronary stents improved the safety of PCI and also 
reduced the incidence of restenosis and abrupt vessel closure. As a result, these techniques 
were also used for a subset group of patients with LMCA disease. Initial experiences were 
performed with bare-metal stents and highly variable results were demonstrated according 
Recommendations according to extent of coronary artery 
disease
CABG PCI
Class Level of 
evidence
Class Level of 
evidence
Left main disease with a SYNTAX score ≤ 22. I B I B
Left main disease with a SYNTAX score 23–32. I B IIa B
Left main disease with a SYNTAX score > 32. I B III B
Three vessel disease with a SYNTAX score ≤ 22. I A I B
Three vessel disease with a SYNTAX score 23–32. I A III B
Three vessel disease with a SYNTAX score > 32. I A III B
Table 1. ESC/EACTS recommendations for the type of revascularization in patients with left main coronary artery 
disease [30].
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to studied patient population. Worse outcomes were published with cardiogenic shock and 
who were not surgical candidates, whereas god results were obtained in elective patients who 
were good surgical candidates. The bare-metal stent era was characterized by high restenosis 
and repeat revascularization rates, and restenosis of the LM stents resulted in sudden cardiac 
deaths [22].
After clinical use of drug-eluting stents, a reduction in restenosis rates renewed enthusiasm 
for PCI in LMCA disease. At first, different series reported better outcomes with drug-eluting 
stents for LMCA disease but their results were limited by selection bias regarding the patient 
characteristics and the anatomical features of LM stem [32]. For better understanding of the 
results, finally properly designed, large-scale randomized controlled trials comparing PCI 
with drug-eluting stents to CABG surgery emerged and they provided important answers to 
the question of PCI vs. CABG surgery for LMCA disease [22].
PCI for LMCA may exist with a broad spectrum of clinical scenarios. The LM stem may 
eventually be injured and closed as a complication of diagnostic cardiac catheterization. This 
iatrogenic injury might not be suitable for emergency operation and this patient may sud-
denly become a candidate for PCI. In a similar fashion, coronary flow of the patient in the 
cath lab for acute MI who has an occluded LM stem may rapidly be restored by PCI rather 
than surgery and this may be life-saving. Different preoperative risk assessment and scor-
ing systems may demonstrate high operative risk for the patient, or the patient himself may 
simply refuse the operation, which automatically puts the patient in the PCI group. The most 
controversial group is the group of patients who are good surgical candidates and willing 
to be operated. Currently, surgery is considered the standard of care for this group. Many 
clinicians feel that PCI should not yet be offered to this group until the results of properly 
performed clinical trials comparing the outcomes of surgery vs. PCI are available and show 
that PCI outcomes are at least equal to those with surgery [22]. If left main PCI is being con-
sidered, it should not be performed immediately after coronary arteriography. The patient 
should hear opinions from a multidisciplinary team prior to deciding on a revascularization 
strategy. Exceptions to this principle include patients who are unstable and need immediate 
revascularization in the catheterization laboratory or those in whom CABG is not an option 
for any reason [8].
In a study designed by Erglis et al. comparing drug eluting stents and bare metal stents for 
the treatment of unprotected LMCA disease, 103 patients with stable angina were assigned 
to receive either paclitaxel-eluting stent or bare-metal stent. All interventions were IVUS 
guided and CB pre-treated before stenting was performed in all patients. All patients were 
scheduled for 6-month follow-up. Follow-up analysis showed binary restenosis in 11 (22%) 
bare-metal stent and in 3 (6%) paclitaxel-eluting stent patients (p = 0.021). The findings 
demonstrated that implantation of paclitaxel-eluting stents was superior to bare-metal 
stent in the large-diameter LM vessel at 6 months [33]. By the highlights of studies and 
improving stent technology, drug-eluting stents are preferred in general use for LMCA 
disease.
In the LMCA disease, the results for distal LM were worse when compared to ostial or mid-
shaft lesions. Although long-term outcomes in patients with ostial/shaft unprotected LMCA 
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lesions were favorable, outcomes in patients with bifurcation lesions treated with stenting of 
both the main and side branches appeared unacceptable [34]. The distal LMCA is the usual 
site of restenosis and the circumflex origin is especially vulnerable to restenosis.
In the ostial involvement, delineating the aorto-ostium by coronary angiography may be dif-
ficult and optimal stent decision may be tricky. The implantation of the stent for ostial LMS 
stenosis must be done with a small protrusion into the aorta to ensure adequate ostium cover-
age. The aorto-ostium may be very rigid due to calcium and has a tendency to recoil. In case of 
heavy calcification, rotational thrombectomy may help reducing calcium load, so that it helps 
balloon and stent expansion and prevents recoil. In most cases of ostial disease, IVUS proves 
very helpful to ensure coverage and proper stent expansion [22].
Distal LMS stenosis can be treated by a single-stent or by a two-stent strategy. The choice 
of the strategy is based on: plaque distribution, the angle between the two branches, the 
diameter of LAD and LCx and the presence of side branch stenosis [6]. Although the data 
are challenging, patients with distal LM stenosis treated with single-stent strategy have a 
TVR rate relatively low (<5%), nearly equivalent to patients with ostial or mid-shaft LM 
stenosis treated by the same strategy [35]. Provisional T-stenting is the most frequent used 
strategy for single-stent strategy. It consists of the deployment of a single stent from LMCA 
to the LAD or LCx, whichever has the highest diameter. T-stenting has an advantage that 
it allows placement of a second stent into the side branch if it is severely narrowed. In 
two-stent strategy, two stents are planned and deployed in one of several different ways 
(culotte method, double kissing crush, etc.) to treat both the main branch and the side 
branch. The lack of randomized data in this area makes it difficult to advocate one strategy 
over another.
In the “Intracoronary Stenting and Angiographic Results: Drug-eluting Stents for Unprotected 
LM Lesions” (ISAR-LM) randomized trial, comparing PCI with sirolimus-eluting stent vs. 
paclitaxel-eluting stent, no significant differences were reported in the composite outcome of 
death, MI, and TLR at 12-month follow-up. No difference was reported also in restenosis and 
2-year LM-specific revascularization [36].
The best available data for long-term outcomes with stenting of LMCAD come from the 
EXCEL and NOBLE randomized trials. EXCEL trial assigned 1905 patients with LMCA dis-
ease of low or intermediate complexity (SYNTAX score ≤ 32) to either PCI with everolimus-
eluting stents or CABG [37]. The primary endpoint, a composite of death from any cause, 
stroke, or MI at 3 years, occurred at a similar rate in both groups. There were no significant 
between-group differences in the three-year rates of the components of the primary endpoint. 
The secondary endpoint of death, stroke, or MI at 30 days occurred less often in patients in 
the PCI group due mainly to a lower rate of MI. The secondary endpoint of death, stroke, 
MI, or ischemia driven revascularization at 3 years occurred more often with PCI. PCI with 
everolimus-eluting stents was noninferior to CABG with respect to the rate of the composite 
endpoint of death, stroke, or myocardial infarction at 3 years.
The NOBLE trial randomly assigned 1201 patients (without ST-elevation MI) to complete 
revascularization with either PCI, using a biolimus-eluting stent, or CABG [38]. The  primary 
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endpoint of major adverse cardiac or cerebrovascular events (a composite of all-cause mor-
tality, nonprocedural MI, any repeat coronary revascularization, and stroke) at 5 years 
occurred more often with PCI attributable mainly to more frequent revascularization in the 
PCI group and a higher rate of stroke, the latter of which is not consistent with all other tri-
als. The findings of this study suggest that CABG might be better than PCI for treatment of 
LM stem CAD.
Sometimes, a patient with acute MI and demonstrated three-vessel disease with involvement 
of LMCA disease may benefit from emergency coronary angioplasty. If the responsible vessel 
for acute MI is the RCA and complicated with cardiogenic shock, direct PTCA for RCA may 
significantly reduce in-hospital mortality and the patient may become a surgical candidate 
for LMCA after evaluation of the mitral valve for ischemic mitral insufficiency for possible 
interventions in a more stable status.
Most of the LM PCI does not require hemodynamic support, but during PCI for LMCA dis-
ease, the operator should be ready for any hemodynamic compromise, slow or no reflow or 
other procedural complications and take necessary precautions. These precautions include 
the placement of intraaortic balloon pump (IABP) or sometimes the support of percutane-
ous LV assist devices in poor LV functions, such as the Impella. Patients more likely to need 
support include those with severe LV dysfunction, occlusion of the right coronary artery, a 
left dominant circulation, and patients in whom the PCI procedure is likely to be complex 
and difficult, thus increasing the ischemic time [22]. In general, careful attention to patient’s 
baseline hemodynamic status before and during the procedure is necessary. Patient with 
instable hemodynamic status or those in whom even brief balloon inflations result in hemo-
dynamic compromise may benefit from the support. As a member of the heart team, a car-
diac surgeon should always be informed before the implementation of PCI for unprotected 
LMCA and the surgical team should be ready for any potential complications and eventu-
ally for emergency CABG.
Patients with a patent bypass graft to either the LAD or LCx, who are considered to be “pro-
tected,” may require LM intervention because of recurrent ischemia. Protected lesions are 
anatomically similar to those that are not previously bypassed. However, their physiology 
during treatment and the consequences of abrupt closure and restenosis are much more for-
giving because of continued flow to the protected territory [8].
8. Surgical treatment of LMCA disease
LMCA disease is an important independent risk factor for increased mortality and morbidity 
at all stages of diagnosis and treatment of CAD. For several decades, CABG was regarded 
as the standard of care for significant LMCA disease in patients eligible for surgery. More 
recently, PCI has emerged as a possible alternative method of treatment for revascularization 
in specifically selected, especially low risk group of patients, except for the life-saving emer-
gency high-risk groups. Besides patient characteristics, lesion location is an important factor 
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for the determination of treatment of choice as well as operator’s experience and technical 
considerations. Stenting of distal stem or bifurcation lesions is technically challenging and 
most of the patients are presented with three-vessel disease which makes them good surgical 
candidates. Although the improvement in stent technology and increased experience of PCI 
techniques by the operators sometimes make the surgery questionable, surgery is still the 
“gold standard” for treatment of LMCA disease [24]. The outcomes of patients with SYNTAX 
score ≥ 34 was better with surgery as compared with PCI CABG surgery, which improves 
survival in patients with significant LMCA disease, three-vessel (and possibly two-vessel) 
disease, or reduced ventricular function, and prolongs and improves the quality of life in 
patients with LM equivalent disease (proximal LAD and proximal LCx), but does not protects 
them from the risk of subsequent MI. In this section, patient selection and CABG methods, 
as well as technical considerations, will be discussed for surgical treatment of LMCA disease. 
Indications of surgery for LMCA disease in ACCF/AHA guideline is summarized in Table 2.
By far, the most common known etiology of LMCA disease is atherosclerosis. Non-atherosclerotic 
causes of LMCA lesions are rare. Since atherosclerosis is a generalized disease affecting the 
whole arterial system in the body, its association should always be kept in mind such as carotid 
artery disease, cerebrovascular disease and peripheral artery disease as well as porcelain aorta 
which make the surgical procedure more challenging.
The incidence of sudden death in patients with critical LMCA disease means that these patients 
should never be thought as patients in the waiting list for elective surgery. Emergency CABG 
is recommended as Class I indication for patients with life-threatening ventricular arrhyth-
mias, which is believed to be ischemic in origin, in the presence of ≥50 LMCA stenosis [17]. 
In a study by Maziak et al. [39], patients in the waiting list for CABG operations were evalu-
ated. In this study, 281 patients over 2145 had critical (≥50%) LM stenosis. The average time 
from angiography to operation was shorter in patients with LMCA disease and the presence 
of LMCA disease did not influence operative mortality, the incidence of low cardiac output 
syndrome or the incidence of perioperative MI. To examine the effect of waiting time on out-
comes, patients with LMS were divided into early (operation 10 days or less after angiogra-
phy) and late revascularization groups (more than 10 days). Operative mortality, low output 
syndrome, and myocardial infarction were similar in the early and late groups. Patients in the 
early group were more likely to have NYHA functional Class IV symptoms, unstable angina, 
or a recent preoperative myocardial infarction. He concluded that carefully selected patients 
with significant LMS can safely wait for operation. But, it should be kept in mind that patients 
with severe symptoms and recently preoperative MI should be allocated for early surgical 
intervention.
The “Heart Team,” made up of clinical or noninvasive cardiologists, cardiac surgeons and 
interventional cardiologists, provides a balanced, multidisciplinary decision-making process. 
Formulation of the best possible revascularization approaches, also taking into consideration 
the social and cultural context, will often require interaction between these branches. Patients 
may need help in making decisions about their treatment and the most valuable advice will 
probably be provided to them by the Heart Team [40].





• CABGinPatientsWithAcuteMI: Emergency CABG is recommended in patients with life-
threatening ventricular arrhythmias (believed to be ischemic in origin) in the presence of LM 
stenosis ≥50% and/or 3-vessel CAD (LoE:C)
• Life-ThreateningVentricularArrhythmias: CABG is recommended in patients with resuscitated 
sudden cardiac death or sustained ventricular tachycardia thought to be caused by significant 
CAD (>50% stenosis of LMCA and/or >70% stenosis of 1, 2, or all 3 epicardial coronary 
arteries) and resultant myocardial ischemia (LoE:B)
• CABGinAssociationWithOtherCardiacProcedures: CABG is recommended in patients 
undergoing noncoronary cardiac surgery ≥50% luminal diameter narrowing of the LMCA or 
≥70% luminal diameter narrowing of other major coronary arteries (LoE:C)
• HeartTeamApproachtoRevascularizationDecisions: A Heart Team approach to revascularization 
is recommended in patients with unprotected LM or complex CAD (LoE:C)
• LeftMainCADRevascularization: CABG to improve survival is recommended for patients with 
significant (>50% diameter stenosis) left main coronary artery stenosis (LoE:B)
Class IIa 
indications
•  Calculation of the STS and SYNTAX scores is reasonable in patients with unprotected LM and 
complex CAD (LoE:B)
• LeftMainCADRevascularization:
 1.  PCI to improve survival is reasonable as an alternative to CABG in selected stable patients 
with significant (>50% diameter stenosis) unprotected LMCAD with: (1) anatomic 
conditions associated with a low risk of PCI procedural complications and a high 
likelihood of good long-term outcome (e.g., a low SYNTAX score [<22], ostial or trunk left 
main CAD); and (2) clinical characteristics that predict a significantly increased risk of 
adverse surgical outcomes (e.g., STS-predicted risk of operative mortality >5%) (LoE:B)
 2.  PCI to improve survival is reasonable in patients with UA/NSTEMI when an unprotected 
LMCA is the culprit lesion and the patient is not a candidate for CABG (LoE:B)
 3.  PCI to improve survival is reasonable in patients with acute STEMI when an unprotected 
LMCA is the culprit lesion, distal coronary flow is <TIMI grade 3, and PCI can be 
performed more rapidly and safely than CABG (LoE:C)
•  Carotid artery duplex scanning is reasonable in selected patients who are considered to have 
high-risk features (i.e., age > 65 years, LMC stenosis, PAD, history of cerebrovascular disease 
(transient ischemic attack (TIA), stroke, etc.), hypertension, smoking, and diabetes mellitus) 
(LoE:C)
•  In the absence of severe, symptomatic aorto-iliac occlusive disease or PAD, the insertion 
of an IAB is reasonable to reduce mortality rate in CABG patients who are considered 




• LeftMainCADRevascularization: PCI to improve survival may be reasonable as an alternative 
to CABG in selected stable patients with significant (>50% diameter stenosis) unprotected 
LMCAD with: (1) anatomic conditions associated with a low to intermediate risk of PCI 
procedural complications and an intermediate to high likelihood of good long-term 
outcome (e.g., low–intermediate SYNTAX score of <33, bifurcation LMCAD); and (2) clinical 
characteristics that predict an increased risk of adverse surgical outcomes (e.g., moderate–
severe chronic obstructive pulmonary disease, disability from previous stroke, or previous 
cardiac surgery; STS-predicted risk of operative mortality >2%) (LoE:B)
•  CABG to improve survival rate may be reasonable in patients with end-stage renal disease 
undergoing CABG for LMCA stenosis of ≥50% (LoE:C)
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The hospital mortality rate for CABG surgery is approximately 1% in low-risk patients, 
with fewer than 3% of patients suffering perioperative myocardial infarction. The most 
consistent predictors of mortality after CABG are urgency of operation, age, prior cardiac 
surgery, female gender, low LV ejection fraction, degree of LM stenosis, and number of ves-
sels with significant stenoses. The most common mode of early death after CABG is acute 
cardiac failure leading to low output or arrhythmias, owing to myocardial necrosis (often 
with features of reperfusion), postischemic dysfunction of viable myocardium, or a meta-
bolic cause, such as hypokalemia. As in cardiac surgery, in general, the risk of perioperative 
MI increases with the degree of cardiomegaly, and in patients who have had preoperative 
infarction [41].
8.1. Myocardial protection for surgery in LMCA disease
The objective of any type of myocardial management during cardiac surgery should target 
on decreasing injury to the myocardium by combination of hypothermia, electromechani-
cal arrest, washout, oxygen and other substrate enhancement and buffering. There is no one 
specific method that ideally describes the myocardial protection as in the LMCA disease. 
It depends on surgeon’s preferences, surgical technique, and surgeon’s desire for complete 
bloodless area during the operation, sequence and timing of proximal anastomoses and costs. 
The optimum strategy for myocardial protection in severe LMCA disease remains unclear not 
only because of different regimens, but also the advanced stenosis of the LM stem resulting in 
uneven distribution of the preferred cardioplegic solution, slow diastolic arrest and delayed 
functional recovery due to pre- and perioperative functional status of the heart in critical LM 
stenosis and recent MI.
The myocardial protection is achieved by either antegrade blood cardioplegia through the 
ascending aorta via right and left coronary ostia in the absence of severe aortic regurgita-
tion or retrograde blood cardioplegia by a special cannula inserted into the coronary sinus 
through the right atrium. Severe obstructive manifestations of CAD are perhaps the best 
examples for the superiority of retrograde cardioplegia. These include LM lesions and acute 
coronary syndromes. In this specific concern of LMCA disease, the cardioplegia distribution 
is not even because of the proximal stenosis and may cause impaired myocardial protec-
tion. Although retrograde cardioplegia results in better distribution, myocardial cooling and 




•  PCI to improve survival should not be performed in stable patients with significant (>50% 
diameter stenosis) unprotected LMCAD who have unfavorable anatomy for PCI and who are 
good candidates for CABG (LoE:B)
Abbreviations: CABG: coronary artery bypass graft; CAD: coronary artery disease; IAB: intraaortic balon; LM: left main; 
LMCAD; left main coronary artery disease; LoE: level of evidence; LVEF: left ventricle ejection fraction; NSTEMI: non-
ST elevation myocardial infarction; PAD: peripheral artery disease; PCI: percutaneous coronary revascularization; UA; 
unstable angina.
Table 2. ACCF/AHA guideline recommendations for left main coronary artery bypass graft surgery [17].
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presence of veno-venous shunts and thebesian channels means that distribution of retro-
grade cardioplegia may not effectively protect the right ventricle and posterior septum [42]. 
A combined approach may be a better alternative for myocardial protection where ante-
grade blood cardioplegia and maintained with continuous retrograde blood cardioplegia 
has been shown to result in reduced postoperative serum troponin I levels and rates of atrial 
fibrillation, compared with approaches using solely antegrade cardioplegia in patients with 
significant LMCA disease [43]. Patients with LMCA disease also have high incidences of 
involvement of RCA occlusion; so, not only the left coronary system, but also the right coro-
nary system is impaired during antegrade cardioplegia route.
A conscious decision to use both the antegrade and retrograde routes of cardioplegia rou-
tinely, delivered in either an alternating sequential fashion or simultaneously, has evolved 
in the practice of some institutions. In our daily practice, we use combined antegrade and 
retrograde cardioplegia technique. In lack of severe aortic insufficiency, half or two-thirds 
of the dose is given through the antegrade perfusion cannula and the remaining solution 
is given through the retrograde cannula. After performing the first distal anastomosis by 
saphenous graft to the LCx system (mainly the best obtuse marginal artery branch), we 
do not wait for completion of time and perfuse the LCx from directly through the anasto-
mosed saphenous vein graft, if the stenosis of LMCA disease is severe (Figure 3). In the 
absence of LAD stenosis, direct perfusion of LCx also allows perfusion of LAD in retro-
grade fashion.
Sometimes slow continuous retrograde perfusion may also be applied for better protection. 
Our goal is primarily good protection of the heart with as short cross-clamp time as possible. 
After completion of LIMA-LAD anastomosis, hot-shot with warm blood cardioplegia is given 
and usually the proximal anastomoses of the saphenous vein grafts to the ascending aorta is 
performed after the heart began to beat by the aid of side-clamp. If the aorta is severely calci-
fied, single-clamp strategy may be used. Also, for better recovery of the heart, we also go on 
perfusing the heart by a line derived from the arterial cannula inserted into each saphenous 
vein grafts during proximal anastomosis stage.
Other preoperative prophylactic or postoperative insertion of the IABP is sometimes advis-
able. In addition to its use in MI with low cardiac output or shock, preoperative insertion is 
often helpful in unstable angina, LM disease with ongoing ischemia, and ischemia leading to 
ventricular arrhythmias. In the era of more complex arterial revascularization for ischemic 
heart disease, IABP support is helpful intraoperatively for pre-bypass support of patients 
with low ejection fraction [44]. When an IABP is used, it is important to understand that 
it is not the final therapy in terms of mechanical support for the failing heart. If the shock 
state persists, as evidenced by a depressed cardiac index, then some form of direct mechani-
cal support must be implemented so as to restore adequate end-organ perfusion. Failure to 
adequately treat a patient in cardiogenic shock will most assuredly result in the patient’s 
demise [41].
8.2. Type of surgery
Since the first CABG was performed in the late 1960s, the standard surgical approach has 
included the use of cardiac arrest coupled with CPB, optimizing the conditions for  construction of 
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Figure 3. During on-pump bypass surgery, anastomosed saphenous vein grafts are perfused before LIMA-LAD anasto-
mosis for better myocardial protection in left main coronary artery disease (in circle).
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 vascular anastomoses to all diseased coronary arteries without cardiac motion or  hemodynamic 
 compromise. Such on-pump CABG has become the gold standard and is performed in about 
80% of subjects undergoing the procedure [17]. Despite the excellent results that have been 
achieved, the use of CPB and the associated manipulation of the ascending aorta are linked with 
certain perioperative complications, including myonecrosis during aortic occlusion, cerebro-
vascular accidents, generalized neurocognitive dysfunction, renal dysfunction, and systemic 
inflammatory response syndrome. To avoid these potential complications, off-pump surgical 
technique was developed by the aid of special cardiac stabilizing devices. This technique is 
also helpful in avoidance of touching the aorta which may be heavily calcified. In 2005, an 
AHA Scientific statement comparing the two techniques concluded that both procedures usu-
ally result in excellent outcomes and that neither technique should be considered superior to 
the other [45].
The LMCAD is known to be an important poor prognostic factor related to morbidity and 
mortality at various stages of CAD. In the past, LMCAD was accepted as a relative contraindi-
cation for off-pump CABG because of the hemodynamic compromise of the patient by chang-
ing the position of the heart. With evolving experience, some centers began to use off-pump 
technique in their routine daily practice and emerging number of reports in the literature have 
proven this method as a safe alternative to CPB. In a review article searching for studies com-
paring the results of on-pump CABG and off-pump CABG in patients with LMCAD, the out-
comes, concerns and controversies were evaluated [46]. The majority of the studies identified 
showed favorable or equal outcomes of OFP when compared to conventional approach. All of 
the studies, apart from two, which showed lower incidence of postoperative deaths, demon-
strated equal mortality rates. Stroke rates were found less in three studies. Less blood trans-
fusions, inotropic use and length of study has been also demonstrated. The main concerns 
of off-pump surgery were hemodynamic instability and less complete revascularization. 
Main controversies were same or favorable outcomes, despite lower number of grafts with 
off-pump surgery, and less stroke rates, despite manipulation of aorta with side-clamping. 
Despite these concerns and controversies off-pump surgery has been proven to be feasible 
and safe as demonstrated by results from numerous studies.
Patients who have had recent MI with impaired LV and patients with dilated ventricles 
may not be ideal candidates for off-pump bypass procedures. Similarly, in patients with 
more than mild mitral insufficiency, grafting the branches of the LCx coronary artery may 
cause hemodynamic instability during the procedure. In such cases, surgery may be best 
managed by performing the revascularization procedure on the beating heart with cardio-
pulmonary support. The aorta is not clamped and cardioplegia is not administered. In such 
conditions, the heart is kept empty, providing optimal myocardial protection and hemody-
namic stability (Figure 4).
Anesthetic management is very important during off-pump surgery. The key to avoiding con-
version to emergency CPB should be proactive by preventing hypotension and low cardiac 
output. Intravascular volumes should be replenished before positioning the heart. The most 
common reason for hypotension is venous return problems. To prevent this, Trendelenburg 
position with turning the patient right-side may be helpful. The most important part for 
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 positioning the heart is placement of the pericardial sutures. If the target vessel is on the left 
side, right side pericardial sutures should be left free and the deep pericardial sutures and the 
left pericardial sutures should be tightened. Generally, lifting the heart to a vertical position 
is relatively well tolerated. After carefully defining the target vessel, stabilizer device (e.g., 
Octopus System, Medtronic Inc. Minneapolis, MN) and their pads should be placed around 
Figure 4. Cardiopulmonary bypass-assisted beating heart surgery. Note that the aorta is not clamped and cardioplegia 
is not administered. In such conditions, the heart is kept empty, providing optimal myocardial protection and 
hemodynamic stability.
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the vessel at diastolic phase and be fixed. After the arteriotomy, placement of intra-arterial 
shunt provides myocardial blood flow continuity, minimizes distal bed ischemia and helps in 
correct suturing. During beating heart surgery, the operative field may become dirty because 
of bleeding; in that case silastic tape traction from proximal and distal portion of the arteri-
otomy may stop bleeding and help for a bloodless area. Carbondioxide mist blower is also 
helpful for clear view of the operating field.
Usually anterior and the most critic vessel should be anastomosed first. In LMCA disease, after 
preparation of the left internal mammarian artery (LIMA), direct anastomosis to LAD provides 
blood flow to LV. LAD artery is usually grafted at distal one-third to one-half where the artery 
normally emerges from the intramyocardial location if suitable. Other LCx obtuse marginal 
branches can be accessed with the heart in vertical position and rotated to the right. Use of apical 
suction devices may help positioning the heart. In LMCA disease, positioning of the heart may 
cause hemodynamic instability, especially after acute MI. After LAD anastomosis, if the hemody-
namic instability persists, the patient may be a candidate for hybrid approach for future PCI. The 
goal of the surgery should be complete revascularization in normal conditions; but any unneces-
sary attempts to provide complete revascularization which threatens his life should be avoided.
8.3. Conduit selection
The effectiveness of CABG in relieving symptoms and prolonging life is directly related to graft 
patency. Because arterial and venous grafts have different patency rates and modes of failure, 
conduit selection is important in determining the long-term efficacy of CABG. The LIMA is 
the conduit of choice for revascularization of LAD distal to the LMCA lesion. LIMA should 
be used to bypass the LAD artery when bypass of the LAD artery is indicated (Class I recom-
mendation for ACCF/AHA guideline for CABG surgery) [17].Since the atherosclerosis is an 
active event, anastomosis should be performed to the best distal area. LIMA provides superior 
short- and long-term patency and clinical outcomes to alternative conduits. Unlike saphenous 
vein grafts, IMA’s are usually >90% patent after 10 years. They are resistant to atherosclerosis 
and release prostacyclin and nitric oxide, thereby causing vasodilation and inhibiting platelet 
function, by their endothelium studies suggesting an improved survival rate in patients under-
going CABG, when the LIMA is used rather than saphenous vein grafts to LAD. This survival 
benefit is independent of the patient’s sex, age, extent of CAD, and LV systolic function [47]. 
Apart from improving survival rate, LIMA grafting of the LAD artery reduces the incidence of 
late MI, hospitalization for cardiac events, need for reoperation and recurrence of angina [48].
Although arterial conduits such as the radial artery have been shown to offer superior long-
term patency to saphenous vein grafts, the risk of arterial graft spasm in the immediate 
postoperative period has discouraged some surgeons from total arterial revascularization 
of LMCA lesions [9]. Tatoulis et al. who analyzed 8420 patients, including 849 with signifi-
cant LMCA disease, did not report adverse sequelae attributable to graft spasm in patients 
with LMCA disease who underwent total arterial grafting [49]. Patients should be informed 
before radial artery harvesting. Usually, the radial artery is harvested from the non-domi-
nant arm of the patient. We routinely perform Doppler ultrasonography for evaluation of 
radial artery. The radial artery diameter >2 mm is usually suitable for a good quality conduit. 
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Dominance of the ulnar artery in hand should also be evaluated by modified Allen test [50]. 
Radial artery graft patency is best when used to graft a left-sided coronary artery with >70% 
stenosis and worst when it is used to bypass the right coronary artery with a stenosis of only 
moderate severity [51]. In technical aspects, we use radial artery grafts for >90% lesions and, 
during harvest, we use ultrasonic/harmonic scissors to avoid heat trauma to the vessel. After 
harvesting the graft, all the fasciae over the radial artery is also cleared longitudinally to 
prevent vasospasm (Figure 5). This maneuver also helps us making a better bleeding control 
from the side branches and provides better vessel diameter. Topical papaverine is also a 
good option for prevention of vasospasm.
Combination of LIMA, right IMA and radial artery may be used for full arterial revasculariza-
tion processes. Some centers also prefer gastroepiploic artery either in case of inappropriate 
LIMA or in combination with LIMA and RIMA for full arterial revascularization concept 
(Figure 6).
Besides these arterial grafts, reversed saphenous vein grafts are commonly used in patients 
undergoing CABG surgery. Their disadvantage is a declining patency with time: about 
10–25% of saphenous vein grafts occlude within 1 year of CABG [52]. An additional 1–2% 
occlude each year during the 1–5 years after surgery; and 4–5% occlude each year between 
6 and 10 years postoperatively. Therefore, 10 years after CABG, 50–60% of saphenous vein 
grafts are patent, only half of which have no angiographic evidence of atherosclerosis [53].
Patient’s age, stenosis degree of the affected coronary artery and hemodynamic status of the 
patient are important factors for overall graft selection. If possible, all patients with LMCA 
Figure 5. Radial artery harvesting with the fascia over the artery opened longitudinally to prevent vasospasm.
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Figure 6. Arterial-only revascularization with LIMA-OM2 and RIMA-LAD anastomoses.
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disease who are candidates for surgery deserve LIMA-LAD anastomosis either with on-pump 
or off-pump CABG surgery. Any surgeon should always target on full revascularization, 
but PCI should also be kept in mind. The heart team should also be in contact with LMCA 
patients not only before the operation, but also after the operation for future interventions or 
medical treatment plan.
9. Conclusion
LMCA disease is still one of the most challenging areas of disease for both cardiovascular sur-
geons and interventional cardiologists today. CABG offers a survival advantage over medical 
therapy for significant LMCA disease since medical therapy alone has been associated with 
poor outcomes. CABG surgery has been accepted as the standard revascularization method 
for LMCA disease for several decades. In the last decade, several randomized controlled tri-
als have shown favorable results for PCI, and the emerging practice in PCI techniques and 
new materials has led to almost routine therapeutic option for a subset group of patients with 
LMCA disease. LMCA disease with low SYNTAX scores (≤22) can be treated either by CABG 
or PCI, whereas SYNTAX score > 32 is an indication for only CABG. The heart team should 
always be in collaboration, give therapeutic options to patients and decide the best treatment 
strategy for the welfare of the patient.
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